美国Quest Diagnostics www.questdiagnostics.com
美国最大的临床诊断公司Quest Diagnostics，2006年收入63亿美元。这家公司发起于1967年，期间经历多次并购，1996年在美国纽交所上市。Quest在美国拥有31个区域性大型诊断中心，155家快速反应实验室，超过2100个病人服务中心，每年诊断超过1亿个标本。目前，美国前三名公司的市场占有率超过60％，市场集中度很高。在欧美和日本等发达国家，独立实验室已经占据临床检验市场的1/3。而中国99％的检验业务仍在医院检验科完成。但相比Quest拥有的3000多项检验项目，中国的大型医院也只有500~1000个项目。

In 1967 in New York City, Dr. Paul Brown launched the clinical laboratory industry with his vision to offer high quality, highly automated and cost-effective clinical testing. The business was named MetPath, for Metropolitan Pathology, and it quickly became the leading independent testing laboratory in the greater New York metropolitan area.
Corning Incorporated purchased MetPath in 1982 and continued to build the company. The business continued to expand and additional companies were acquired, including Damon in 1993, Maryland Medical Laboratory in 1994 and Bioran in 1994. Also in 1994, Corning acquired Nichols Institute, world-renowned for esoteric testing. Today, Nichols Institute is Quest Diagnostics' esoteric testing laboratory and research and development center. Because Nichols Institute labs perform tests rarely run in most routine or hospital laboratories, they see a large number of unusual cases on a regular basis, one reason its medical directors are frequently sought by physicians for consultations.
On December 31, 1996, Corning Incorporated spun off the laboratory testing business to its shareholders, establishing Quest Diagnostics as an independent company trading on the New York Stock Exchange under the Symbol "DGX." With the acquisition of SmithKline Beecham Clinical Laboratories (SBCL) on August 16, 1999, Quest Diagnostics became the nation's leading provider of diagnostic testing, information and services.
Quest Diagnostics continued to expand through a combination of organic growth and business acquisitions. Health information technology (HIT) provider MedPlus, Inc., was acquired in 2001, marking the company's commitment to providing physician and hospital customers with online access to essential patient information at the point of care. In 2002, the company acquired American Medical Laboratories (AML), and its laboratory in Chantilly, Virginia, became an East Coast outpost of the Nichols Institute, allowing Quest Diagnostics to offer highly specialized esoteric testing on both coasts.
In 2003 the company completed its acquisition of Unilab Corporation, solidifying its presence throughout the state of California. In 2005 the company acquired LabOne, expanding its presence in Kansas and Ohio and the drugs of abuse testing business. Additionally, the acquisition enabled the company to enter into a testing related business, providing services to the life insurance industry.
When it acquired premier infectious disease testing provider Focus Diagnostics, Inc., in 2006, Quest Diagnostics added a recognized world leader in infectious and immunologic diseases with specific expertise in developing new diagnostics. Focus has been first with a range of important tests for public health, from SARS to West Nile Virus to Lyme disease and human Parvovirus. The acquisition further strengthened the company's position as the leading provider and developer of esoteric tests for hospitals and physicians.
The company also acquired the manufacturer of the proprietary InSure® FIT™ colorectal cancer screening test Enterix, Inc., in 2006. InSure FIT is a non-invasive, fecal immunochemical colorectal cancer screening test that requires no dietary or medication restrictions, is included in American Cancer Society annual screening guidelines, and provides greater sensitivity and specificity than guaiac-based colorectal cancer screening tests.
Quest Diagnostics strengthened its position in the growing area of point-of-care testing when it acquired HemoCue in 2007, a Swedish-based company that stands as the leading international provider in near-patient testing for hemoglobin, with a growing share in professional glucose and microalbumin testing. HemoCue handheld systems are broadly used in physicians' offices, blood banks, hospitals, diabetes clinics and public health clinics.
In 2007 the company completed the acquisition of AmeriPath, a cancer diagnostics company focused on dermatopathology, anatomic pathology and molecular diagnostics. The combined expertise and testing capabilities positioned Quest Diagnostics as the world's leading provider of cancer diagnostics services.
With the acquisition of California-based Pathway Diagnostics in 2008, a specialized provider of biomarker assay development, validation, and testing services, Quest Diagnostics further strengthened its position as a world leader in biomarker services and as a provider of clinical trials services.
Quest Diagnostics offers the most extensive clinical testing network in the United States, operating laboratories in most major metropolitan areas, as well as in Mexico, the United Kingdom and, as of 2008, in the growing market in India.
Today, Quest Diagnostics performs testing for more than half a million patients each day, serving approximately half of the physicians and hospitals in the United States.